SCHEMBL30869138

SCHEMBL30869138

CC(C)(C)OC(=O)N(CCCO)Cc1ccc(OC(F)(F)F)c(Cl)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SSTR4 P31391 1/20 0.39
SCN3A Q9NY46 5/20 0.38
CA14 Q9ULX7 1/20 0.38
ROCK2 O75116 1/20 0.37
PPARD Q03181 2/20 0.37
PPARA Q07869 2/20 0.37
HCRTR1 O43613 1/20 0.37
HCRTR2 O43614 1/20 0.37
PPARG P37231 1/20 0.35
SCN9A Q15858 2/20 0.35
PTGDR2 Q9Y5Y4 1/20 0.35
SCN1A P35498 1/20 0.35
KCNH2 Q12809 1/20 0.35
SCN5A Q14524 1/20 0.35
SCN2A Q99250 1/20 0.35
SCN8A Q9UQD0 1/20 0.35
SCN10A Q9Y5Y9 1/20 0.35
MEN1 O00255 1/20 0.34
ALDH1A1 P00352 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26049694 0.97 CA14 (0.40) SSTR4SCN3ACA14ROCK2PPARD
SCHEMBL30694800 0.97 CA14 (0.40) SSTR4SCN3ACA14ROCK2PPARD
SCHEMBL27374719 0.90 CA14 (0.36) SSTR4SCN3ACA14ROCK2PPARD
SCHEMBL29900268 0.90 SCN3A (0.39) SSTR4SCN3ACA14ROCK2PPARD
SCHEMBL26048981 0.90 SCN3A (0.39) SSTR4SCN3ACA14ROCK2PPARD
SCHEMBL27321821 0.89 SCN3A (0.37) SSTR4SCN3ACA14ROCK2PPARD
SCHEMBL27371903 0.87 SCN3A (0.40) SCN3AROCK2PPARDPPARAPPARG
SCHEMBL30869094 0.86 SCN3A (0.38) SSTR4SCN3AROCK2PPARDPPARA
SCHEMBL29900237 0.86 PPARD (0.38) SCN3ACA14ROCK2PPARDPPARA
SCHEMBL30803437 0.85 SCN3A (0.37) SCN3AROCK2PPARDPPARAHCRTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260085062-A1 NOVEL COMPOUNDS AS CK2 INHIBITORS CAMBRIDGE ENTPR LTD (GB) 2026-03-26 US disclosed
EP-4584249-A1 NOVEL COMPOUNDS AS CK2 INHIBITORS Cambridge Enterprise Limited (GB) 2025-07-16 EP disclosed
WO-2024052702-A1 NOVEL COMPOUNDS AS CK2 INHIBITORS CAMBRIDGE ENTERPRISE LIMITED (GB) 2024-03-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260085062-A1 NOVEL COMPOUNDS AS CK2 INHIBITORS CSNK1A1, CSNK1G1, CSNK2A3 SSTR4 2794/4885SCN3A 209/4885CA14 1736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.